Dr Rasha Abu Eid

Dr Rasha Abu Eid
BDS, PhD, PGCert (HELT)

Senior Lecturer

Overview
Dr Rasha Abu Eid
Dr Rasha Abu Eid

Contact Details

Telephone
work +44 (0)1224 555155
work +44 (0)1224 437351
Email
Address
The University of Aberdeen Office A107, Institute of Dentistry
Office 3:47 / 08 Institute of Medical Sciences
Lab 4:51 Institute of Medical Sciences
Foresterhill
Aberdeen, AB25 2ZD 
Web Links

Dr Abu Eid is one of the Editors for the Research Topic: Advances in Head and Neck Cancer Immunology and Immunotherapy. Frontiers in Oncology/ Frontiers in Immunology - special issue.

The Research topic is live online http://journal.frontiersin.org/researchtopic/6212/advances-in-head-and-neck-cancer-immunology-and-immunotherapy

Biography

I qualified as a dentist in 2001, where I graduated from the Faculty of Dentistry at the University of Jordan. During my years of study, I developed a keen interest in Oral Pathology, and in particular in the pathology of malignant and premalignant oral lesions. I therefore joined a postgraduate research program in Oral Pathology at the University of Birmingham, England. The focus of my research was the quantification of oral cancer and pre-cancer growth patterns using digital imaging and innovative mathematical descriptors of morphology and complexity such as Fractal geometry. I successfully completed my PhD in 2005, and worked as a Research fellow in the same institute.

In 2006, I joined the academic staff at the Faculty of Dentistry at the University of Jordan as an Assistant Professor in Oral Pathology. In addition to being involved in teaching several modules, I also pursued my research and assumed several administrative responsibilities such as being the Dean Assistant for Students’ affairs and being an active member of different committees.

In 2009 I joined the Academic staff of the newly established Dental School at the University of Aberdeen. I contributed to the development of the curriculum and to teaching in several courses. I also assumed several administrative duties and was the Theme Lead for Dental Health and Disease for the first three years of the course.

During my time in Aberdeen, I studied for my PGCert in Higher Education Teaching and Learning, and I completed the course in July 2011 and became a fellow of the Higher Education Academy.  

In 2011, I was successful in securing a prestigious research fellowship grant from the King Hussein Institute for Biotechnology and Cancer to conduct state of the art research in the field of cancer immunology in USA. My fellowship was split between the National Cancer Institute/ National Institutes of Health and Georgia Regents University (Currently Augusta University), where I later became an Assistant Research Scientist. The focus of our research group was T cell Biology and the modulation of the immune system as part of cancer immune therapy.

In October 2016, I re-joined the Academic staff at the University of Aberdeen Dental School as a Senior Lecturer in Oral Sciences. My primary research focus is T cell biology and head and neck cancer immunology in addition to different applications of digital pathology.

I am currently the lead for the Head and Neck Cancer Research Theme at the Dental School. I am also a member of the Immunity, Infection and Inflammation research program at the Institute of Medical Sciences.

Research

Research Interests

My main research interests focus on various aspects of head and neck cancer. This includes the objective diagnosis and quantification of oral premalignant and malignant lesions using digital pathology in addition to cancer immunology and immune therapy.

Current Research

Morphological and Immunological Characterization of HPV Positive Head and Neck Cancer and Pre-cancer

(Funded by Friends of Anchor, NHS Endowment)

The incidence of head and neck cancer (HNC) has increased in UK both in males and females and is still on the rise with the highest rates reported in Scotland. This increase is attributed to changes in risk factors such as alcohol and tobacco consumption in addition to human papilloma virus (HPV) infections. HPV infection affects younger age groups and is therefore associated with HNC and premalignant lesion diagnoses at younger ages than traditionally reported.

Premalignant lesions predispose to malignant transformation and should be monitored to aid in the early detection of malignant transformation. Classically, premalignant lesions were classified into mild, moderate and severe epithelial dysplasia. This classification system suffered from subjectivity leading to noticeable discrepancies in inter-and intra-examiner consistency in diagnosing these lesions. Therefore, there is a move towards simpler more reproducible classification systems that divide premalignant lesions into low and high grades.

To aid the classification dilemma and ultimately improve the ability to predict malignant changes, several studies were performed that applied reproducible and objective parameters to analyse tissue sections from different pathological entities. Our group used morphological features such as the complexity of the epithelial connective tissue interface (ECTI), and descriptors of cell shape and size  to characterize oral cancer and precancer in addition to normal oral mucosa (Abu Eid and Landini, 2003; 2005). It is hoped that such criteria can be implemented in the design of new classification systems that will better predict  malignant transformation potential and provide guidelines for clinical management.

Despite advances in treating HNC, the mortality rate is still high which is mainly due to the late diagnosis of these cases. Therefore, there is great need for developing diagnostic tools that aid in early detection. Additionally, the development of novel therapies is essential. Among the advances in cancer treatment, cancer immunotherapy is one of the most important developments. HNCs positive for HPV are candidates for cancer immunotherapy. Our group has reported promising anti-tumour efficacy in TC-1 murine mouse model, which expresses HPV E7 using different formulations of HPV E7 peptide vaccines, including different adjuvants (Abu Eid et al., 2014) and listeria based E7 vaccine (Mkrtichyan et al., 2014). The anti-tumour therapeutic efficacy of these vaccines was significantly enhanced when combined with PI3k/Akt pathway inhibitors (Abu Eid et al., 2014; 2017; Ahmad et al. 2017). Furthermore, in cervical cancer patients, we showed that Pre-Immature Dendritic Cells pulsed with HPV E7 are capable of inducing specific immune responses against the E7 peptide despite the advanced disease (Rahma et al., 2014). We further showed that combining HPV E7 vaccines with antibodies targeting PD-1 enhance  anti-tumour therapeutic efficacy through modulating the tumour microenvironment (Mkrtichyan et al., 2014). It is therefore integral to understand the role of PD-1 and its ligands (PDL-1 and PDL-2) in HNC (Shrimali et al., 2015).

To further the research into HNC immunotherapy and the classification of premalignant lesions, full understanding of the immune response in addition to complete characterization of morphological changes in HPV positive and negative premalignant and malignant lesions is crucial.

The Effect of Oligohydramnios on Tissue and Cellular Morphometry in the Developing Foetal Murine Lung. 

Collaboration with Dr Tanbir Najrana and Dr Juan Esteban-Sanchez, the Department of Paediatrics, Alpert Medical School of Brown University. Women & Infants Hospital of Rhode Island, USA

(Funded by the National Institute of General Medical Sciences of the National Institutes of Health Department of Pediatrics; Kilguss Research Core of Women & Infants Hospital of Rhode Island).

Oligohydramnios resulting from membrane ruptures can cause pulmonary hypoplasia in humans. This has been confirmed experimentally in different animal models and attributed to the decrease in lung distention as result of a decrease in lung fluid in the developing air spaces.

We have characterized a mouse model of pulmonary hypoplasia secondary to severe oligohydramnios and reported significant changes in the differentiation of different cell types, in particular Type I cells, where the level of T1-α (a marker for Type I cells) was significantly reduced in OH both at the mRNA and protein levels. Furthermore, we found that oligohydramnios affects vasculogenesis and apoptosis without altering cell proliferation. Interestingly, we reported a major decrease in developing lung spaces and a significant decrease in cell size and a change in cell shape as a result of oligohydramnios using different descriptors of particle size and shape (Najrana et al., 2016; 2017).

Currently, we are looking into different rescue models for foetal pulmonary hypoplasia using different murine models.

Modulators of T Cell Function 

Collaboration with Dr Frank Ward, University of Aberdeen

(Funded by Friends of Anchor)

Cancer immunotherapy is among the most important developments in cancer treatment. Despite its impressive successes, the response in patients is often limited and short lived. This is due to factors that hamper the immune response against tumour cells. 

Regulatory CD4 T-cells (Tregs) are major contributors to the suppressive tumour microenvironments and immune modulators that selectively mitigate these cells are needed. 

The expression of co-inhibitory molecules by tumour cells is another tumour mediated immune escape mechanism that leads to the suppression of effector T-cells. Immune checkpoint inhibitors that block the interaction between these co-inhibitory molecules and their receptors have shown remarkable results in enhancing anti-tumour therapeutic efficacy. 

Additionally, cancer immunotherapy is hindered by the short-lived anti-tumour effect due to the exhaustion of tumour-specific effector CD8 T-cells. The phenotype and differentiation status of CD8 T-cells have major influences on their function. There is intense interest in manipulating immune modulators to maximise their cytotoxicity and enhance their longevity as part of cancer immunotherapy. 

Small molecule inhibitors that target different signalling pathways within T cells have been used successfully to modulate T-cell responses by selectively inhibiting Tregs and/or generating superior antigen-specific CD8 T-cells with enhanced proliferative ability, survival and functional capability (Abu Eid et al. 2014, 2015, 2016, 2017). Furthermore, immune checkpoint inhibitors have proven successful in modulating the anti-tumour immune response. 

The aim of our work is to identify targets for selective modulation of immune cells while understanding the specific mechanisms that control T cell development and responses. Results will guide combination therapies with different immune modulators as part of cancer treatment.

Research Grants

  • Friends of Anchor
  • TENOVUS Scotland
  • NHS Grampian Endowment Grant
Further Info

External Responsibilities

Memberships: 

  • Fellow of the Academy of Higher Education, UK (July 2011 till current date)
  • British Society for Immunology
  • Scottish Society of Cytomics
  • The Association of Science Educators in Dentistry (ASEiD), formerly the Association of Basic Science Teachers in Dentistry (ABSTD)
  • British Society of Oral Medicine

Chairing conference sessions, conference organizing committee membership and editorial responsibilities:

  • Chair for the "Using Fractals in Image Processing" Session in Fourth International Symposium on “Interdisciplinary Approaches in Fractal Analysis”, Bucharest, Romania. May 2009.
  • Member of the international program committee for the sixth International Workshop on Interdisciplinary Approaches in Fractal Analysis (IAFA-2013), Part of the 19th International Conference on Control Systems and Computer Science. Bucharest, Romania. May 2013
  • Member of the international program committee for the seventh International Workshop on Interdisciplinary Approaches in Fractal Analysis (IAFA-2015), Part of the 20th International Conference on Control Systems and Computer Science. Bucharest, Romania. May 2015
  • Member of the international program committee for the eighth International Workshop on Interdisciplinary Approaches in Fractal Analysis (IAFA-2017), Part of the 21st International Conference on Control Systems and Computer Science. Bucharest, Romania. May 2017
  • Member of the international program committee for the ninth International Workshop on Interdisciplinary Approaches in Fractal Analysis (IAFA-2019), Part of the 22nd International Conference on Control Systems and Computer Science. Bucharest, Romania. May 2019
  • Certified reviewer on Publons.com https://publons.com/author/420217/rasha-abu-eid#profile
  • Review Editor in Genitourinary Oncology, part of the journal(s) Frontiers in Oncology.
  • Editor for the Research Topic: Advances in Head and Neck Cancer Immunology and Immunotherapy. Frontiers in Oncology/ Frontiers in Immunology. http://journal.frontiersin.org/researchtopic/6212/advances-in-head-and-neck-cancer-immunology-and-immunotherapy

Admin Responsibilities

  • Chair of the Research Committee at the Institute of Dentistry  (April 2018- January 2020)
  • Postgraduate Research Coordinator at the Institute of Dentistry
  • Member of the Institute of Dentistry Executive Committee (April 2018- January 2020) 
  • Member of the School of Medicine Medical Sciences and Nutrition Industrial Liaison Committee
  • Academic lead for Oral Biology

Research Team

PhD Students

Prarthna Clare

https://www.abdn.ac.uk/people/r01mpc17

Nadisha Piyarathne

https://www.abdn.ac.uk/people/r01nsp17

Badri Risheh

https://www.abdn.ac.uk/people/b.risheh.18

Farah Al-Fatyan

https://www.abdn.ac.uk/people/f.al-fatyan.19

Katie Hanna

https://www.abdn.ac.uk/people/k.hanna.19

Subarnarekha Chatterji

https://www.abdn.ac.uk/people/s.chatterji.19

 

 

Publications

Publications 

Update